Treatment of pulmonary aspergilloma with itraconazole.
In a 12 month open study of itraconazole in pulmonary aspergilloma nine patients received oral itraconazole 200 mg daily for six months followed by further itraconazole or observation for a further six months. There was no change in the serum IgG specific for Aspergillus fumigatus (mean (SE) change -4% (10%)) or symptoms of chronic cough and haemoptysis. In two of the three patients who continued treatment beyond six months symptoms and radiographic appearances improved and a temporary reduction in A fumigatus specific IgG occurred in one patient. Further experience of the effects of longer treatment are needed before oral itraconazole can be recommended for aspergilloma.
Campbell
J H
JH
Department of Respiratory Medicine, Glasgow Royal Infirmary.
Winter
J H
JH
Richardson
M D
MD
Shankland
G S
GS
Banham
S W
SW
D000908:Antibodies, Fungal / Q000032:analysis; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008168:Lung / Q000000981:diagnostic imaging; D008172:Lung Diseases, Fungal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011859:Radiography
D000908:Antibodies, Fungal; D000935:Antifungal Agents; D007074:Immunoglobulin G; D017964:Itraconazole; D007654:Ketoconazole